| Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China. | |
| | |
MedLine Citation:
|
PMID: 22430608 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
To compare the efficacy and safety of RFT (retuximab, fludarabine, pirarubicin) with RCTVP (retuximab, cyclophophamide, pirarubicin, vindesine and prednisone) in 248 indolent B-cell non-Hodgkin's lymphoma (NHL) patients. Two hundred and forty-eight patients with indolent B-cell NHL were treated with combined chemotherapy, including RFT and RCTVP, from January 2002 to December 2010 in Tianjin Cancer Hospital. The rate of response, toxicity and long-term survival for the two regimens were analyzed retrospectively. For the previously untreated patients, overall response rate for RFT arm and RCTVP arm was 71.7 and 70.6%, and complete response rate was 47.5 and 54.9%, respectively (P > 0.05). For the refractory and relapsed patients, overall response (OR) rate and complete response (CR) rate were significantly improved in the RFT arm versus the RCTVP arm (P < 0.05). There were no statistically significant differences in overall survival (OS) between treatment groups. Comparing with RCTVP regimen, fludarabine-based treatment was associated with superior PFS both in previously untreated, refractory and relapsed patients. WHO grades 3 and 4 hematological adverse events were more common in the RFT arm. Neurotoxicity was more common in the RCTVP arm. For the previously untreated patients, there was no difference between RFT arm and RCTVP arm on OR and CR rates. For the refractory and relapsed indolent B-cell NHL patients who received RFT regimen achieved higher OR and CR rates compared with RCTVP-treated patients. No differences in OS were noted. RFT regimen was associated with superior PFS both in previously untreated, refractory and relapsed patients. RFT regimen is effective and well tolerated for patients with untreated, refractory and relapsed indolent B-cell NHL. |
| | |
Authors:
|
Yun Hou; Hua-Qing Wang; Yi Ba |
Related Documents
:
|
22349598 - Bilateral synchronous tibial periosteal osteosarcoma with familial incidence. 22331838 - Long-term results of adjuvant gemcitabine plus s-1 chemotherapy after surgical resectio... 22882088 - Overexpression of chromatin assembly factor-1 p60, poly(adp-ribose) polymerase 1 and ne... 22609108 - Phase ii trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine... 18984268 - Expression of bcl-2 in olfactory neuroblastoma and its association with chemotherapy an... 22349598 - Bilateral synchronous tibial periosteal osteosarcoma with familial incidence. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-3-20 |
Journal Detail:
|
Title: Medical oncology (Northwood, London, England) Volume: - ISSN: 1559-131X ISO Abbreviation: - Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-3-20 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9435512 Medline TA: Med Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Lyphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimal Exploitation for a Commercial Fishing Model.
Next Document: Exponential synchronization of stochastic Cohen-Grossberg neural networks with mixed time-varying de...